AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01002664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 soft-gel placebo capsules Qd for 12 weeks
Study NCT01610232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photon stimulation by light-emitting diodes (LEDs)
Description: Treadmill training with the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate. The average power and power density on the skin were 100 mW and 39 mW/cm2, respectively. The treatment time was 45 min bilaterally in both thighs. These parameters led to an approximate fluence of 108 J/cm2.
Study NCT01610232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Treadmill training without the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate
Study NCT03856996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stable CH505TF gp120
Description: Administered by IM injection in the deltoid of the non-dominant arm
Study NCT03856996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transient CH505TF gp120
Description: Administered by IM injection in the deltoid of the non-dominant arm
Study NCT03856996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)
Description: Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm
Study NCT00633737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress reduction intervention
Description: In addition to standard care, patients in the intervention group will receive a one-hour individually delivered programme administered once by a psychologist at least 3 days prior to surgery. This session aims to reduce stress and involves teaching relaxation and guided imagery exercises. Patients are provided a CD (or audiotape)of the relaxation instructions to take home and practice once a day.
Study NCT01003639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
Study NCT01003639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
Study NCT01003639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Formal weight loss counselling program
Description: Teleconference, web-based from central location, using site visits and subject self-assessment tools
Study NCT01003639 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Formal weight loss counselling program
Description: Teleconference, web-based from central location, using site visits and subject self-assessment tools
Study NCT02914379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3337641
Description: Administered orally
Study NCT03126032 — intervention group
Intervention type: OTHER
Intervention: GlycoCheck™-System
Description: Consecutive, sublingual measurements of endothelial glycocalyx with GlycoCheck™-System will be obtained at presentation, as well as during the inpatient treatment of the patients with suspected sepsis.~Blood sample will be drawn in all groups at time of assessment. Besides that, in patients with suspected sepsis blood samples will be drawn for further microbiologic and laboratory analysis at day 1 and day 7 of their hospital stay.
Study NCT01903408 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB
Description: The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)
Study NCT01790321 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LSF-filtering device
Description: LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 NTU turbidity reduction), bacteria (>Log 6 reduction), viruses (>Log 4 reduction) and cysts (>Log 3 reduction). Zinc fortification is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, >100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
Study NCT01790321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSF-filtering device
Description: LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 NTU turbidity reduction), bacteria (>Log 6 reduction), viruses (>Log 4 reduction) and cysts (>Log 3 reduction). Zinc fortification is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, >100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
Study NCT00741715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530
Description: oral administration once daily in the evening with dinner
Study NCT00741715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: oral administration once daily in the evening with dinner
Study NCT00741715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: oral administration once daily in the evening with dinner
Study NCT00741715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration once daily in the evening with dinner
Study NCT02735837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Group
Description: Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
Study NCT02735837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo topical gel
Description: placebo topical gel was put into the periodontal pocket using an insulin syringe
Study NCT02055573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready To Learn (RTL)
Description: See arm description
Study NCT02055573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: All Babies Cry (ABC)
Description: See arm description
Study NCT04443387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
Study NCT02191722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reading comics booklet
Study NCT04570852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LiDCO
Description: We plan to elucidate the pathophysiology and molecular subtypes of acute pancreatitis in order to develop specific biomarkers and identify new drug targets. The evaluation will include an analysis of the impact of obesity and the metabolic profile during the disease course of acute pancreatitis.~Supportive treatments will be registered including an assessment of the fluid balance based on the fluid intake and loss and weight. Bioimpedance will be assessed at admission/day1, day 2, day 3,
Study NCT01942044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus element, Xience prime, and Nobori
Study NCT01942044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promus element, Xience prime, and Nobori
Study NCT01104246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testerone Transdermal System
Description: Transdermal testosterone applied daily for 4 weeks
Study NCT03264781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclofem
Description: Intramuscularly injection 0.5 ml of Cyclofem or placebo
Study NCT03264781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclofem
Description: Intramuscularly injection 0.5 ml of Cyclofem or placebo
Study NCT02128347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Patient Portal
Description: RelayHealth is a web-based application that allows patients and clinicians to communicate through a secure, password protected online electronic portal with data transfer capabilities. The system allows physicians and nurses to view patient questions, patient data and transmit messages to patients in response to questions or after clinic visits in an electronic message. In addition, patients can be made aware of upcoming investigations or clinic visits. Patients can also use the interface to identify any proposed changes (which would minimize recall mistakes after clinic visits) and submit queries pertaining to dialysis. Both patients and clinicians are made aware of new messages through email prompt, which moderates the asynchronous nature of electronic communication. Telephone communication can be maintained, but reserved for more urgent issues that require immediate assistance.
Study NCT00247078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: widow spider antivenom
Description: 3 vials of antivenom capable of neutralizing 600 LD50 of L. mactans
Study NCT00247078 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02289508 — intervention group
Intervention type: DEVICE
Intervention: Ultrasonic cardiac output monitor
Description: An Ultrasonic Cardiac Output Monitor, a non-invasive Doppler ultrasonography, is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD). It has been compared favorably with a wide range of standard techniques, including PATD, with good interobserver reliability. USCOM may help on monitoring HF and suggesting proper treatment in order to reduce the mortality of adHF.
Study NCT02289508 — intervention group
Intervention type: DEVICE
Intervention: Echocardiography
Description: 2D-echo is a conventional standard-of-care tool for non-invasive hemodynamic assessments in adults. The use of 2D-echo requires highly trained personnel, and assessments may take anywhere between 30-45 minutes. It is used to find out the ejection fraction and to compare the haemodynamic parameters with USCOM in this study.
Study NCT01917812 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Digital Activity Tracker
Study NCT01917812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Activity Tracker
Study NCT01917812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Text Messaging
Study NCT03041701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Once every 2 weeks beginning on day 0.
Study NCT00154804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin,Surgery, CCRT
Study NCT00585013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Study NCT04443387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
Study NCT05448586 — intervention group
Intervention type: DRUG
Intervention: Opioid
Description: Use of balanced anesthesia including opioids during anesthesia for gynecologic cancer surgery
Study NCT05817487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity interval training (HIIT)
Description: Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The training sessions in the HIIT group involved five high-intensity intervals of 4 minutes each (running or walking on a treadmill) at 85% VO2max interspersed with 3 minutes of low-intensity walking.
Study NCT05817487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: crossover point(COP) exercise training
Description: Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The COP exercise training sessions involved 45 minutes of continuous exercise at the COP on a treadmill.
Study NCT01506765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl-Cysteine (NAC)
Description: Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
Study NCT01506765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-Acetyl-Cysteine (NAC)
Description: Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
Study NCT04103424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short-term Exercise Training
Description: Participants will perform 2-weeks of supervised exercise training on a stationary bike.
Study NCT00941538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Experimental: Screening with EBV VCA/EBNA1-IgA testing
Description: Participants in the screening towns will be offered screening tests. Those with high-risk scores will be referred to a diagnostic workup examination using fiberoptic endoscopy examination and nasopharyngeal biopsies if suspicious lesions is observed.
Study NCT01040286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: 2.0 mg
Study NCT01040286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: 2.5mg
Study NCT03767985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dichoptic video game therapy
Description: Dichoptic video gaming for 1 hour per week, viewed through the Oculus Rift.
Study NCT03767985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occlusion therapy
Description: Occlusion therapy for 2 hours per day, 7 days a week
Study NCT03367546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and Marrow Transplant
Description: Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)
Study NCT00688090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: MKC1106-MT
Description: Cancer Vaccine, Immunotherapy
Study NCT00688090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: MKCC1106-MT
Description: Cancer Vaccine, Immunotherapy
Study NCT03160482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.
Study NCT01378377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered in fasted state at a dose of 45 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
Study NCT01378377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered in fasted state at a dose of 75 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
Study NCT02739490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Training Group
Description: Performs oriented exercise segmental stabilization lumbar-pelvic.
Study NCT01378377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus will be administered at a dose of 12.5 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
Study NCT01378377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus will be administered at a dose of 25 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
Study NCT03597009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (TVEC)
Description: Talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles, with or without nivolumab
Study NCT03597009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg IV) will be co-administered with talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles in the Dose Level 2 cohort
Study NCT00672386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ16269110
Description: 5 mg twice daily for 12 weeks
Study NCT00672386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ16269110
Description: 10 mg twice daily for 12 weeks
Study NCT00672386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ16269110
Description: 15 mg twice daily for 12 weeks
Study NCT02529397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Working Memory Training
Description: Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using an adaptive cognitive training program which becomes increasingly challenging as the participant masters each level. Behavioral classes will teach the principles of weight management and exercise.
Study NCT02529397 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-adaptive cognitive training
Description: Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using a non-adaptive cognitive training program. Behavioral classes will teach the principles of weight management and exercise.
Study NCT00857441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting balloon
Description: Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
Study NCT00857441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liberté
Description: Bare metal stent
Study NCT00857441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liberté
Description: Bare metal stent
Study NCT00857441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA balloon catheter
Description: Percutaneous transluminal coronary angioplasty catheter
Study NCT00857441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus
Description: Paclitaxel eluting stent
Study NCT03758118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline
Description: Citicoline administered in oral solution